Animal StudyHighlighted
MHID-13886872024Journal of Evolutionary Biochemistry and Physiology
M. M. Artemieva, T. A. Kuropatkina, V. V. Shishkina, D. V. Serebryanaya, D. A. Adasheva, O. S. Medvedev, et al.
Molecular hydrogen demonstrates antioxidant and anti-inflammatory properties. It has been
shown to have a protective effect in several cardiovascular diseases. The aim of this work was to
investigate the effect of breathing atmospheric air containing 4% hydrogen on the degree of development
of monocrotaline-induced pulmonary hypertension and associated lung tissue inflammation, as well as
the degr
Animal StudyHighlighted
MHID-2957577PMID: 381373622023Biomedicines
Tatyana Kuropatkina, Dmitrii Atiakshin, Fedor Sychev, Marina Artemieva, Tatyana Samoilenko, Olga Gerasimova, et al.
Hydrogen has been shown to exhibit selective antioxidant properties against hydroxyl radicals, and exerts antioxidant and anti-inflammatory effects. The monocrotaline-induced model of pulmonary hypertension is suitable for studying substances with antioxidant activity because oxidative stress is induced by monocrotaline.
On day 1, male Wistar rats were subcutaneously injected with a water–alcohol
Animal Study
MHID-7818899PMID: 352644922022Experimental Animals
Kohei Kawakami, Hiroyuki Matsuo, Takaya Yamada, Ken-ichi Matsumoto, Daigoro Sasaki, Masato Nomura
Hydrogen-rich water (HW) has been suggested to possess antioxidant properties of value in treatments of lifestyle diseases and for prevention of latent pathologies. To date, the potential benefits of HW against the deleterious effects of excessive salt intake and hypertension have not been investigated. Here, we first examined the effects of HW or HW supplemented with 0.1% ascorbic acid (HWA) on s
Observational Study
MHID-22983482022Renal Replacement Therapy
Susumu Uemura, Yoshitaka Kegasa, Keigo Tada, Taichi Tsukahara, Shigeru Kabayama, Tae Yamamoto, et al.
Background: Reportedly, dialysis solutions containing molecular hydrogen (H2) might ameliorate patient-reported fatigue in hemodialysis (HD) patients. However, it is unknown whether its impact might differ with different H2 levels.
Method: This single-arm, prospective observational study examined 105 patients on chronic HD (62 males; mean age, 66 years; mean HD duration, 117 months). All patients
Clinical TrialHighlighted
MHID-1269854PMID: 362782212022Frontiers in Pharmacology
Boyan Liu, Xue Jiang, Yunbo Xie, Xiubin Jia, Jiashuo Zhang, Yazhuo Xue, et al.
Objective: To explore the effect of a low-dose hydrogen–oxygen (H2-O2) mixture inhalation in midlife/older adults with hypertension.
Methods: This randomized, placebo-controlled trial included 60 participants with hypertension aged 50–70 years who were randomly divided into Air group (inhaled placebo air) or H2-O2 group [inhaled H2-O2 mixture (66% H2/33% O2)]. Participants in both groups were tre
Clinical TrialHighlighted
MHID-6639794PMID: 362906572022Antioxidants
Branislav Kura, Mária Szántová, Tyler W. LeBaron, Viliam Mojto, Miroslav Barancik, Barbara Szeiffova Bacova, et al.
Non-alcoholic fatty liver disease (NAFLD) is a liver pathology affecting around 25% of the population worldwide. Excess oxidative stress, inflammation and aberrant cellular signaling can lead to this hepatic dysfunction and eventual carcinoma. Molecular hydrogen has been recognized for its selective antioxidant properties and ability to attenuate inflammation and regulate cellular function. We admin
Clinical TrialHighlighted
MHID-1947207PMID: 346511332021Critical Care Explorations
Alexis R. Cole, BS, Francesca Sperotto, MD, James A. DiNardo, MD, Stephanie Carlisle, Michael J. Rivkin, MD, Lynn A. Sleeper, ScD, et al.
BACKGROUND: Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled hydrogen gas at doses required for a clinical efficacy study.
DESIGN: Prospective, single-arm study.
SETTING: T
Animal Study
MHID-4743523PMID: 332440272020Scientific Reports
Kazuhisa Sugai, Tomoyoshi Tamura, Motoaki Sano, Shizuka Uemura, Masahiko Fujisawa, Yoshinori Katsumata, et al.
A recent clinical study demonstrated that haemodialysis with a dialysate containing hydrogen (H2) improves blood pressure control in end-stage kidney disease. Herein, we examined whether H2 has a salutary effect on hypertension in animal models. We subjected 5/6 nephrectomised rats to inhalation of either H2 (1.3% H2 + 21% O2 + 77.7% N2) or control (21% O2 + 79% N2) gas mixture for 1 h per day. H2
